08:33 EDAP EDAP TMS SA's Ablatherm-HIFU Successful in Focal Treatment of Prostate Cancer (1.76 ) Co announced today that successful treatments have been performed at the St-Augustin Urology Clinic in Bordeaux , France utilizing EDAP's Ablatherm High Intensity Focused Ultrasound for a focal approach to eradicate prostate cancer tumors.
08:27 SCANX Gapping down In reaction to disappointing earnings/guidance: EDS -26.6%, DG -4.4% (also announces 25.0 mln share secondary offering), WAG -0.4%.
Other news: TAST -9.1% (still checking), FTE -1.9% (following exec comments), GMCR -2.6% (trading lower with SBUX), CEDC -2% (announces restatement of prior reported financial statements), SBUX -1.9% (announces agreement to acquire La Boulange Bakery), JAZZ -0.7% (discloses update related to warning letter; received Form FDA 483 at conclusion of FDA inspection conducted in May 2012), AMZN -0.5% (Amazon Publishing acquires Avalon Books).
Analyst comments: BRCD -3.3% (downgraded to Hold from Buy at ThinkEquity).
08:17 SCANX Gapping up In reaction to strong earnings/guidance: JASO +13.5%, SHFL +1.8%, LAYN +1.7% (ticking higher).
M&A related: OPXT +17.5% (determined unsolicited offer to be acquired for $1.40 is not superior to previously announced merger with Oclaro), AMLN +4.8% (Bloomberg discusses that AMLN may draw bids between $25-29/share; Pfizer has dropped out of bidding, according to reports).
Other news: GNOM +12.7% (announces restructuring plan and review of strategic alternatives), WPRT +8.7% (Westport Innovations and Caterpillar announce agreement to develop natural gas technology for off-road equipment), GALE +8.1% (announces NeuVax (E75) improves disease-free survival at 60-month median follow-up), ALSK +8% (ticking higher, GNCMA and ALSK sign definitive agreements to form The Alaska Wireless Network), ARRY +5.6% (announced MEK162 shows 'promising' clinical activity in ongoing Phase 2 trial), RIMG +3.4% (announces key milestone for Qumu; Qumu's contracted commitments are now expected to be more than $6 mln), IMGN +3.1% (positive mention on MadMoney), HPQ+1.1% (Hewlett-Packard is seeking $4 bln from Oracle over disputes database software, according to reports).
Analyst comments: FIO +3.1% (Fusion-io upgraded to Buy from Neutral at Sterne Agee).
08:03 NEPT Neptune Technologies sees Q1 revs CDN$6.0-6.2 mln vs CDN$5.42 mln Capital IQ single est (3.41 ) ''The krill industry as a whole is vibrant; delivering double digit growth. Krill oil is the fastest growing ingredient in the whole Omega-3 market, which is great news as it reflects greater awareness from the consumers. Neptune's NKO, being first in its class, is gaining momentum worldwide in Asia, Oceania as well as Europe, while continuing great progression in the US mass market where Neptune 's products, while dominating the health store channel, can now be found in large retail chains. We are thrilled and are foreseeing sustained growth in the upcoming quarters."
09:17 CUR Neuralstem updates ALS Stem Cell Trial progress; Emory University Institutional Review Board approves amendment (0.92 ) Co announced that the Emory University Institutional Review Board (IRB) approved the amendment to the ongoing Phase I trial evaluating Neuralstem's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The amendment permits the return of three previously-treated patients to the trial to receive additional injections of cells. This modification to the protocol was approved earlier by the Food and Drug Administration (FDA). Implementation was contingent upon IRB approval, which has now been secured. "Bringing patients back for a second set of injections should they meet the inclusion requirements at the time of surgery, or giving new patients both lumbar and cervical injections, is a major step forward toward testing the maximum safe dosing of our cell therapy," said Richard Garr, Neuralstem President & CEO. "We have been encouraged by the results of the trial to date, and are eager to commence treating patients with this increased dosage."
09:14 OPK Opko Health to acquire stake in Israeli Hepatitis B vaccine manufacturer; Financial terms of the transaction were not disclosed (4.54 ) Co has entered into a definitive agreement to acquire a forty-five percent stake in a private Israeli company that produces a third-generation hepatitis B vaccine ("Sci-B-Vac") in its state of the art biologics manufacturing facility in Rehovot. Sci-B-Vac is currently marketed in Israel and has received marketing authorizations in several countries. Financial terms of the transaction were not disclosed.
News 
Market Data 
Discover 
